BCR and acute myeloid leukemia: To determine whether the B-cells from AML patients had molecular evidence of selection and mutation, we sequenced the B-cell receptor (BCR) complementarity-determining region 3 (CDR3) region of the immunoglobulin heavy (IGH) chain.